Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

NCT05462717 is registered in ClinicalTrials.gov with Revolution Medicines, Inc. as lead sponsor.

NCT NCT05462717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05462717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Lead sponsor
Revolution Medicines, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 19, 2022
Completion date
September 30, 2027
Enrollment
222 (estimated)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, colorectal cancer (crc), non-small cell lung cancer (nsclc), pancreatic ductal adenocarcinoma